Sign Up
OverviewAPI
Systemic Bio, a 3D Systems company, will present innovative human-relevant datasets at upcoming conferences to assess drug-induced liver injury and pharmacokinetics. Their advanced liver model aims to enhance albumin production, CYP activity, and urea production, while a novel model simultaneously assesses anti-tumor therapeutic efficacy and liver injury. This cutting-edge bioprinting technology allows for early-stage pharmaceutical drug development and the generation of human-relevant therapeutic insights.

Ask a question